These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23433962)

  • 1. Efficacy and safety of interferon-gamma-targeted therapy in Crohn's disease: a systematic review and meta-analysis of randomized controlled trials.
    Cui D; Huang G; Yang D; Huang B; An B
    Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):507-13. PubMed ID: 23433962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab for induction of remission in Crohn's disease.
    MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis.
    Chandar AK; Singh S; Murad MH; Peyrin-Biroulet L; Loftus EV
    Inflamm Bowel Dis; 2015 Jul; 21(7):1695-708. PubMed ID: 25856769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Hanauer S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporine for induction of remission in Crohn's disease.
    McDonald JW; Feagan BG; Jewell D; Brynskov J; Stange EF; Macdonald JK
    Cochrane Database Syst Rev; 2005 Apr; (2):CD000297. PubMed ID: 15846602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients.
    Kawalec P; Moćko P
    J Comp Eff Res; 2018 Feb; 7(2):101-111. PubMed ID: 29115855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review and meta-analysis of anti-adhesion molecule therapy in patients with active Crohn's disease.
    Li Y; Tian Y; Yu C; Zhu W; Li J
    Scand J Gastroenterol; 2009; 44(12):1435-42. PubMed ID: 19883269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.
    Hommes DW; Mikhajlova TL; Stoinov S; Stimac D; Vucelic B; Lonovics J; Zákuciová M; D'Haens G; Van Assche G; Ba S; Lee S; Pearce T
    Gut; 2006 Aug; 55(8):1131-7. PubMed ID: 16507585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of immunoregulators and antibiotics in fistulizing Crohn's disease: a systematic review and meta-analysis of placebo-controlled trials.
    Nikfar S; Mirfazaelian H; Abdollahi M
    Curr Pharm Des; 2010; 16(33):3684-98. PubMed ID: 21143147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of natalizumab for multiple sclerosis and Crohn's disease: a meta analysis].
    Li YY; Li YP; Sun X; Wang L; Wen J; Cheng L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Oct; 32(5):533-42. PubMed ID: 21050557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.
    Ford AC; Sandborn WJ; Khan KJ; Hanauer SB; Talley NJ; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):644-59, quiz 660. PubMed ID: 21407183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis.
    Ford AC; Bernstein CN; Khan KJ; Abreu MT; Marshall JK; Talley NJ; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):590-9; quiz 600. PubMed ID: 21407179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
    Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
    Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
    Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of antibiotics in patients with Crohn's disease: a systematic review and meta-analysis.
    Su JW; Ma JJ; Zhang HJ
    J Dig Dis; 2015 Feb; 16(2):58-66. PubMed ID: 25421072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis.
    Shah ED; Farida JP; Siegel CA; Chong K; Melmed GY
    Inflamm Bowel Dis; 2017 Apr; 23(4):570-577. PubMed ID: 28230558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.